REcovery from DEXmedetomidine-Induced Unresponsiveness (REDEX): A Study Protocol for a Single Center, Parallel Arm, Non-Randomized, Controlled Pilot Trial in Healthy Volunteers
Open Access
- 1 June 2025
- journal article
- research article
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 17, 1259-1269
Abstract
Purpose: Dexmedetomidine (DEX) is a well-tolerated sedative drug that induces a sleep-like state. DEX sedation offers a model to study transitions between different states of consciousness (indicated by, eg, behavior, the electroencephalogram (EEG), or transcranial magnetic stimulation (TMS) evoked EEG responses). However, the effects of repeated DEX exposure on recovery are poorly understood and will be investigated in this pilot study. Participants and Methods: We aim to enroll 12 healthy volunteers (6 females, 6 males). Although we do not expect TMS-EEG to interfere with DEX sedation, due to the paucity of evidence this study uses a parallel arm design (TMS-EEG, non-TMS-EEG). Participants will be sedated twice, one week apart, and responsiveness monitored by a click-task to auditory beeps. A 64-channel EEG and additional physiological signals will be recorded. Cognition and vigilance tests will be performed before sedation (baseline), after return of responsiveness (ROR), and before discharge. TMS-EEG will be performed at baseline, during sedation, and during recovery. Using a smartwatch and questionnaires, we will assess sleep quality, sleepiness, and experiences during sedation and TMS-EEG. Results: We will report the difference of time to ROR between the first and second study visit, and explore potential differences across sex and study arms. We will evaluate state transitions by comparing responsiveness, traditional EEG signatures, TMS-evoked EEG responses (ie, perturbational complexity index), and report on cognition and vigilance test performance. Conclusion: This pilot trial will report on the effect of repeated DEX exposure on the recovery period, and the investigation of state transitions will advance our scientific understanding of altered states of consciousness. REDEX will provide valuable insights and data for designing future DEX sedation studies. Moreover, we will report on the potential of biological sex as a confounding factor and the feasibility of TMS-EEG under DEX.Keywords
This publication has 40 references indexed in Scilit:
- Depth of sedation with dexmedetomidine increases transcranial magnetic stimulation-evoked potential amplitude non-linearlyBritish Journal of Anaesthesia, 2023
- Oestrous cycle affects emergence from anaesthesia with dexmedetomidine, but not propofol, isoflurane, or sevoflurane, in female ratsBritish Journal of Anaesthesia, 2023
- Measuring Consciousness in the Intensive Care UnitNeurocritical Care, 2023
- Breathe–squeeze: pharmacodynamics of a stimulus-free behavioural paradigm to track conscious states during sedation☆British Journal of Anaesthesia, 2023
- Sex and gender differences in anesthesia: Relevant also for perioperative safety?Best Practice & Research Clinical Anaesthesiology, 2021
- Clinical Pharmacokinetics and Pharmacodynamics of DexmedetomidineClinical Pharmacokinetics, 2017
- Stratification of unresponsive patients by an independently validated index of brain complexityAnnals of Neurology, 2016
- Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care SettingDrugs, 2015
- Sample size of 12 per group rule of thumb for a pilot studyPharmaceutical Statistics, 2005
- Characterization of the selectivity, specificity and potency of medetomidine as an α2-adrenoceptor agonistEuropean Journal of Pharmacology, 1988